## SEQUENCE LISTING

DT12 Rec'd PCT/PTO 1 0 JAN 2005

<110> TRANSGENE S.A.

<120> Modified adenoviral fiber ablated in binding to cellular receptors containing glycosaminoglycans or sialic acid

<130> mutants fibre HS-

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 581

<212> PRT

<213> Adenovirus serotype 5

<400> 1

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro 1 5 10 15

Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro 20 25 30

Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro Gly Val Leu Ser 35 40 45

Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu 50 55 60

Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly Asn Leu Thr Ser 65 70 75 80

Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys Thr Lys Ser Asn 85 90 95

Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr Ser Glu Ala Leu 100 105 110

Thr Val Ala Ala Ala Pro Leu Met Val Ala Gly Asn Thr Leu Thr 115 120 125

Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile 130 135 140

Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln 145 150 155 160

Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr Leu Thr Ile Thr 165 170 175

Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu Gly Ile Asp Leu 180 185 190

Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
195 200 205

Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu Thr Val Ala Thr 210 215 220

WO 2004/007537 PCT/IB2003/003336

Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln Thr Lys Val Thr Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala 250 Gly Gly Leu Arg Ile Asp Ser'Gln Asn Arg Arg Leu Ile Leu Asp Val 265 Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln 280 285 Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp Ile Asn Tyr Asn 295 Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser Lys Lys Leu Glu 305 310 315 Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser Pro Asn Ala Pro 345 Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly Leu Glu Phe Asp 360 Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly Leu Ser Phe Asp 375 380 Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn Asp Lys Leu Thr 3.90 Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Arg Leu Asn Ala Glu 410 Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys Gly Ser Gln Ile Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser Leu Ala Pro Ile Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg Phe Asp Glu Asn Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu Tyr Trp Asn Phe 475 Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr Asn Ala Val Gly 485 490 Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala 505 Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly Asp Lys Thr Lys 520 Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln Glu Thr Gly Asp 535 540 Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp Asp Trp Ser Gly 545 555 . 550

WO 2004/007537 PCT/IB2003/003336

His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser Tyr Thr Phe Ser 565 570 575

Tyr Ile Ala Gln Glu 580

<210> 2

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mutagenesis
 oligonucleotide S408E

<400> 2

gcatttagtc tacagttagg ctctggagct ggtgtggtcc ac

42

<210> 3

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: mutagenesis
 oligonucleotide A494D

<400> 3

gttaggcata aatccaacgt cgtttgtata ggctgtgcc

39

<210> 4

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: mutagenesis
 oligonucleotide A503D

<400> 4

accgtgagat tttggatagt ctgataggtt aggcataaa

39

<210> 5

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: mutagenesis oligonucleotide T404G

<400> 5

ctacagttag gagatggagc gggcccggtc cacaaagtta gcttatc

47

<210> 6

<211> 39

<212> DNA

<213> Artificial Sequence

<220>			
<223>	Description of Artificial Sequence: mutagenesis oligonucleotide A406K		
<400>	6		
-		39	
-			
.010.			
<210>	•		
<211><212>			
	Artificial Sequence		
\213/	Altificial Sequence		
<220>			
<223>	Description of Artificial Sequence: mutagenesis		
	oligonucleotide V452K		
<400>			
aagato	gagca ctttgctttg ttccagatat tgg	33	
<210>	•		
<211>			
<211>	·		
	Artificial Sequence		
12117			
<220>			
<223>	Description of Artificial Sequence: mutagenesis		
	oligonucleotide S555K		
		•	
<400>		20	
gtggc	cagac cagtoccact taaatgacat agagtatgo	39	
<210>-	9		
<211>			
<212>	DNA		
<213>	Artificial Sequence		
<220>			
<223>	Description of Artificial Sequence: mutagenesis		
	oligonucleotide K506Q/H508K		
<400>			
	rggca gttttaccct tagactgtgg ataagctgat aggtt	45	
<210>	10		
<211>	60		
<212>			
<213>	Artificial Sequence		
40005			
<220>	Description of Artificial Company, mutagenesis		
<b>\</b> 2237	Description of Artificial Sequence: mutagenesis oligonucleotide 12 aa linker	41	
	origonaciaociae iz an ilinei		
<400>	10		
	ttctt tagctgccgg gagcagaggc ggaggcggag gcgctgggtt cttgggcaat	60	
<210>			
<211>			
	LINA		

WO 2004/007537 PCT/IB2003/003336

26

<213>	Artificial Sequence
<220>	
<223>	Description of Artificial Sequence: mutagenesis oligonucleotide 7K ligand
<400>	— <del>-</del>
cacaa	acgat ctttacttct tctttttct tctttttgga tccgggagcg aggcggag 58
<210>	12
<211>	26
<212>	DNA
<213>	Artificial Sequence
<220>	
<223>	Description of Artificial Sequence:mutagenesis oligonucleotide BstBI site
<400>	12

tgaaaaatga ttcgaaattt tctgca .